Literature DB >> 15029256

Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma.

Martin Ebinger1, Leonore Senf, Olga Wachowski, Wolfram Scheurlen.   

Abstract

Methylation of promoter regions of CpG-rich sites is an important mechanism for silencing of tumor suppressor genes (TSG). To evaluate the role of tumor suppressor genes caspase-8 (CASP8), TIMP-3, E-cadherin (CDH1), p16INK4A, and MGMT in medulloblastoma tumorigenesis, 51 medulloblastomas (46 primary tumor specimens, 5 cell lines) were screened for methylation of promoter linked CpG-islands. For CASP8, we examined the 5' UTR region that has been shown to be associated with expression of CASP8. As detected by methylation specific PCR, methylation rate was low for TIMP-3 (3% of tumor samples; 1/5 cell lines), for MGMT (0% of tumor samples; 1/5 cell lines), for p16INK4A (2% of tumor samples; 2/5 cell lines) and for CDH1 (8% of tumor samples; 1/4 cell lines). CASP8, however, was methylated in 90% of tumor samples and 4/5 cell lines examined. Screening other tumor entities for CASP8 methylation, we found a similarly high level in 6 neuroblastoma cell lines in contrast to 5 osteosarcoma-, 4 Ewing's sarcoma- and 6 non-embryonic tumor cell lines without any increased promoter methylation. From our results we conclude that methylation of the CASP8 5' UTR region may play a role in inactivation of CASP8 in neural crest tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029256     DOI: 10.1007/BF02893403

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  27 in total

1.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8.

Authors:  J L Bodmer; N Holler; S Reynard; P Vinciguerra; P Schneider; P Juo; J Blenis; J Tschopp
Journal:  Nat Cell Biol       Date:  2000-04       Impact factor: 28.824

2.  Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma.

Authors:  T J Zuzak; D F Steinhoff; L N Sutton; P C Phillips; A Eggert; M A Grotzer
Journal:  Eur J Cancer       Date:  2002-01       Impact factor: 9.162

3.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.

Authors:  T Teitz; T Wei; M B Valentine; E F Vanin; J Grenet; V A Valentine; F G Behm; A T Look; J M Lahti; V J Kidd
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility.

Authors:  M C Frühwald; M S O'Dorisio; Z Dai; S M Tanner; D A Balster; X Gao; F A Wright; C Plass
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

5.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

Review 6.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

7.  Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

Authors:  M A Grotzer; A Eggert; T J Zuzak; A J Janss; S Marwaha; B R Wiewrodt; N Ikegaki; G M Brodeur; P C Phillips
Journal:  Oncogene       Date:  2000-09-21       Impact factor: 9.867

8.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

Authors:  K E Bachman; J G Herman; P G Corn; A Merlo; J F Costello; W K Cavenee; S B Baylin; J R Graff
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

9.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Authors:  C Friesen; I Herr; P H Krammer; K M Debatin
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  17 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

3.  Retrospective protein expression and epigenetic inactivation studies of CDH1 in patients affected by low-grade glioma.

Authors:  Pietro Ivo D'Urso; Oscar Fernando D'Urso; Carlo Storelli; Giuseppe Catapano; Cosimo Damiano Gianfreda; Antonio Montinaro; Antonella Muscella; Santo Marsigliante
Journal:  J Neurooncol       Date:  2010-12-03       Impact factor: 4.130

Review 4.  Caspase-8 as a therapeutic target in cancer.

Authors:  Dwayne G Stupack
Journal:  Cancer Lett       Date:  2010-09-03       Impact factor: 8.679

Review 5.  Old, new and emerging functions of caspases.

Authors:  S Shalini; L Dorstyn; S Dawar; S Kumar
Journal:  Cell Death Differ       Date:  2014-12-19       Impact factor: 15.828

6.  Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.

Authors:  Dolly G Aguilera; Chandra M Das; Neeta D Sinnappah-Kang; Celine Joyce; Pete H Taylor; Sijin Wen; Martin Hasselblatt; Werner Paulus; Greg Fuller; Johannes E Wolff; Vidya Gopalakrishnan
Journal:  J Neurooncol       Date:  2009-01-16       Impact factor: 4.130

7.  Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.

Authors:  Jennifer A Anderton; Janet C Lindsey; Meryl E Lusher; Richard J Gilbertson; Simon Bailey; David W Ellison; Steven C Clifford
Journal:  Neuro Oncol       Date:  2008-07-29       Impact factor: 12.300

Review 8.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

Review 9.  Molecular diagnostics of gliomas: state of the art.

Authors:  Markus J Riemenschneider; Judith W M Jeuken; Pieter Wesseling; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2010-08-17       Impact factor: 17.088

10.  Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas.

Authors:  Joel I Pritchard; James M Olson
Journal:  Cancer Genet Cytogenet       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.